

Avasimibe

Catalog No: tcsc5695



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

166518-60-1

Formula:

$C_{29}H_{43}NO_4S$

Pathway:

Metabolic Enzyme/Protease

Target:

Acyltransferase

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 28 mg/mL (55.81 mM)

Alternative Names:

CI-1011;PD-148515

Observed Molecular Weight:

501.72

Product Description

Avasimibe is a ACAT inhibitor including ACAT-1 and ACAT-2


In vitro: 1) Avasimibe has beneficial on plasma lipids and direct antiatherosclerotic activity, independent of lipid effects, in various animal models of hypercholesterolemia

2) Avasimibe enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.

In vivo: 1) The reference for administration is daily dosages up to 1000 mg/d for up to 2 weeks and 750 mg/d for up to 8 weeks.

2) Avasimibe reduced plasma apoB levels by 20% in A-PLUS when given at a dose of 750 mg.

3) Avasimibe can potentially lowered plasma cholesterol levels in ApoE*3-Leiden mice and considerably reduced atherosclerotic lesion area in addition to its cholesterol-lowering effect.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!